How effective is margetuximab? Is there a cure rate?

Margetuximab (Margetuximab) is a humanized anti-HER2 monoclonal antibody, mainly used to treat HER2-positive advanced or metastatic breast cancer. It has been structurally optimized through engineering. Compared with traditional trastuzumab (trastuzumab), it has been modified in the Fc segment. Enhanced binding ability to Fcγ receptors in the immune system, thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). This allows margetuximab to exhibit stronger anti-tumor effects in some patients.

Clinical studies (such asSOPHIA Phase III trial) showed that margetuximab combined with chemotherapy can prolong the progression-free life of patients with HER2-positive breast cancer compared with trastuzumab combined with chemotherapy. Extended survival (PFS), especially in patients carrying the CD16A-158F allele, the effect is more obvious. This genotype is very common in the general population, so margetuximab may provide clinical benefit to more patients. However, its overall survival rate (OS) advantage has not yet reached statistical significance, and further research is still needed to confirm it.

In terms of "cure rate", margituximab is currently mainly used in the treatment stage of advanced or recurrent metastatic breast cancer. The main goals of this type of disease are often to control the disease, delay the progression, and improve the quality of life. Although significant remission or even long-term progression-free survival can be achieved in some patients, a “cure” in the strict sense is still relatively rare. Therefore, margetuximab is regarded more as an effective disease control method rather than a radical cure.

In short, margituximab, as a new generation of anti-HER2 targeted drugs, shows better efficacy and immune activity than traditional antibodies in specific groups of people, especially for patients with certain genetic backgrounds. Although a universal cure is not yet possible, it has become an important weapon in the treatment of advanced HER2-positive breast cancer, and its indications are constantly being expanded and combination drug strategies are optimized.

Reference materials:https://www.drugs.com